In an era when increasing demands are being made on the world’s healthcare services, generic and biosimilar medicines provide a major benefit to society by ensuring patient access to quality, safe and effective medicines while reducing the cost of pharmaceutical care.

The International Generic Pharmaceutical Alliance (IGPA) was founded in March 1997 as an international network of generic medicines associations. The name of the organization was changed in September 2015 to the International Generic and Biosimilar Medicines Association (IGBA) to reflect the evolving nature of the industry.


Vision and Mission

Our vision is to promote the widest possible access to generic and biosimilar medicines with high quality, safety and efficacy, support international harmonized pathways for the registration of those medicines, and a strong commitment by members to standards agreed by the International Council for Harmonization (ICH) and WHO accredited regulators.



  • IGBA launches a biosimilar medicines information campaign

    February 01 2018 - Today, the International Generic and Biosimilar medicines Association (IGBA) launched an information campaign on biosimilar medicines. The foundation of this campaign is the IGBA biosimilar medicines public slide deck[1]. Access to well-referenced information is fundamental to improving Read More
  • IGBA congratulates the Australian government for maintaining their biologics naming convention and for strengthening pharmacovigilance

    January 29 2018 - The International Generic and Biosimilar medicines Association (IGBA) welcomes the Australian Government's decision to maintain the existing naming convention for biological, including biosimilar, medicines, that is to continue using the Australian biological name (without a specific identifier Read More
  • IGBA welcomes new member Indian Pharmaceutical Alliance (IPA)!

    2018-01-01 - The IGBA welcomes the Indian Pharmaceutical Alliance (IPA) to its membership. The IPA represents Indian research-based national pharmaceutical companies. This addition to the IGBA membership is significant in widening the IGBA representation, which now covers this important region. Read More
  • The IGBA Biosimilars Committee has developed a communication slide deck on biosimilar medicines

    2017-11-09 - If you wish to use any part of this slide deck, please contact us at \n This email address is being protected from spambots. You need JavaScript enabled to view it. . We would be happy to share this with Read More
  • Ingrid Schwarzenberger, new Chair of the IGBA Biosimilars Committee

    June 13 2017 - IGBA is pleased to announce today the nomination of Ingrid Schwarzenberger, Head Global Regulatory Affairs at Sandoz Biopharmaceuticals, as the new Chair of the IGBA Biosimilars Committee. Ingrid has played a leading role in the establishment of Read More
  • European Experience and Evidence of Physician-led Switching of Biological Medicines Give Hope to Patients around the World

    March 14, 2017 - On 9th March, IFPMA launched jointly with EFPIA and EBE a position paper entitled Considerations for physicians on switching decisions regarding biosimilars. Physician-led switching of biological medicines is a well-known medical practice. Although data on the frequency Read More
  • IGBA Statement on the Final Report of the United Nations Secretary General’s High Level Panel on Access to Medicines

    November 15, 2016 – Geneva, Switzerland – The International Generic and Biosimilar Medicines Association (IGBA) believes that generic and biosimilar medicines can play a fundamental role in improving access to high quality medicines for patients worldwide. Read More
  • 1
  • 2
  • 3
  • 4
  • 5

Joint 23rd Medicines for Europe and 20th IGBA Annual Conference

Joint 22nd Medicines for Europe and 19th IGBA Annual Conference

18th Annual IGPA Conference

Contact Info


Rue d'Arlon, 50
B-1000 Brussels, Belgium

Telephone: +32 (0)2 736 84 11
Fax: +32 (0)2 736 74 38
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.